ClinicalTrials.gg
CompletedNCT05514249Updated Oct 20, 2026

Treatment of a Single Patient With CRD-TMH-001

A Phase 1 interventional study of CRD-TMH-001 in Duchenne Muscular Dystrophy, sponsored by Cure Rare Disease, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years to 28 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Cure Rare Disease, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.
Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 28 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
169th of 172
1 · median 25
Started
2022
with 14 others
Phase 1
32 of 233
3 open now
Registered
183rd of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 169th largest by enrollment of the 172 interventional ones that give a count, is one of 15 that started in 2022, is one of 32 in phase 1, and was the 183rd registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 28 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The study is a single patient study intended to understand the effects of a gene-editing therapeutic to treat a rare mutation of Duchenne muscular dystrophy.

Read the detailed description

The objective of the study is to assess the safety and preliminary efficacy of CRD-TMH-001 after intravenous administration for a period of 1 year with long-term follow-up out to 15 years.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne
  • Muscular Dystrophy
  • CRISPR
  • gene-editing
04

Who can participate

Ages eligible
18 Years to 28 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of
  • Confirmation of genetic mutation
  • Confirmation of absence of elevated AAV9 NAbs

Exclusion criteria

Exclusion Criteria:

- Any significant medical issue(s) (past or current) that would, in the opinion of the Principal Investigator (PI), prevent this patient from being dosed.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Single patient

    Single dose of CRD-TMH-001 administered by IV

    Drug: CRD-TMH-001

Interventions

  • DrugCRD-TMH-001

    Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.

06

What researchers measure

Primary outcomes

  1. To assess the safety of CRD-TMH-001

    To assess the safety and tolerability of the therapeutic by measuring both serious and non-serious adverse events.

    Time frame: 1 year

07

Study locations

1 site
  • UMass Chan Medical School
    Worcester, Massachusetts 01655, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2022, 1 month.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 1 month is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2023 → Oct 2022 and completion Sep 2023 → Oct 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 24, 2022
StartActual
Aug 31, 2022
Primary completionActual
Oct 12, 2022was Sep 2023
CompletionActual
Oct 12, 2022was Sep 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 20, 2026
Primary completion
Sep 2023→Oct 12, 2022 (actual)
Oct 20, 2026
Study completion
Sep 2023→Oct 12, 2022 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Status unknown→Completed
    Primary completion Sep 2023→Oct 12, 2022 (now actual)
    Study completion Sep 2023→Oct 12, 2022 (now actual)
    + 3 other changes: index terms, verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05514249
Lead sponsor
Cure Rare Disease, Inc
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Aug 31, 2022
Primary completion
Oct 12, 2022
Completion
Oct 12, 2022
Last update
Oct 20, 2026

Study contacts

Brenda Wong, MD
principal investigator · UMass Chan Medical School
Medical Affairs
study director · Cure Rare Disease

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion